Literature DB >> 18467909

An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy.

Praveen Sharma1, Barjesh C Sharma, Vinod Puri, Shiv Kumar Sarin.   

Abstract

BACKGROUND AND AIM: Minimal hepatic encephalopathy (MHE) is associated with poor quality of life and increased work disability. Treatment with lactulose and probiotics has shown some benefit. We compared lactulose with probiotics and a combination of lactulose plus probiotics in the treatment of MHE. PATIENTS AND METHODS: One hundred and ninety cirrhotic patients without overt encephalopathy [Child's A grade 71 patients (37.4%), Child's B grade 72 patients (37.9%), Child's C grade 47 patients (24.7%)] were evaluated by psychometry (number connection tests A and B or figure connection tests A and B) and P300 auditory event-related potential (P300ERP). MHE was diagnosed by abnormal psychometry and/or P300ERP. Patients were randomized to receive lactulose [group A (n=35): dose 30-60 ml/day], probiotics [group B (n=35): dose 1 capsule three times/day, each capsule contained Streptococcus faecalis 60 million, Clostridium butyricum 4 million, Bacillus mesentricus 2 million, lactic acid bacillus 100 million] and lactulose plus probiotics [group C (n=35)] for 1 month. Response was defined by normalization of the abnormal test parameters.
RESULTS: MHE was diagnosed in 105 (55.2%) patients. Of the 105 patients, 75 (71%) had both abnormal psychometry and P300ERP, whereas 90 (86%) had abnormal psychometry alone, and 89 patients (85%) had abnormal P300ERP alone. Significant improvement was seen in abnormal psychometry tests (group A: n=31 vs. n=12, group B: n=29 vs. n=14, group C: n=30 vs. n=10), P300ERP (group A: 376.8+/-22.3 vs. 344.3+/-30.6 ms, group B: 385.4+/-28.5 vs. 355.5+/-27.9 ms, group C: 387.7+/-27.5 vs. 347.7+/-31.5 ms) and venous ammonia levels (group A: 102.3+/-63.1 vs. 69.3+/-33.3 micromol/l, group B: 108.2+/-37.5 vs. 75.7+/-33.0 micromol/l, group C: 96.3+/-27.7 vs. 68.7+/-28.4 micromol/l) in lactulose, probiotics and a combination of lactulose plus probiotics groups after treatment. Normalization of abnormal psychometry and P300ERP was seen in 54.8, 51.6 and 56.6% of patients treated with lactulose, probiotics and lactulose plus probiotics groups, respectively.
CONCLUSION: A total of 55% of the patients with cirrhosis had MHE. Lactulose or probiotics or combinations of both are equally effective in the treatment of MHE.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18467909     DOI: 10.1097/MEG.0b013e3282f3e6f5

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  35 in total

1.  Canadian regulations and legal ramifications for hepatic encephalopathy: a descriptive analysis.

Authors:  Henry H Nguyen; Mark G Swain; Philip Wong; Stephen E Congly
Journal:  CMAJ Open       Date:  2018-12-03

Review 2.  Probiotics and liver disease.

Authors:  Vishal Sharma; Shashank Garg; Sourabh Aggarwal
Journal:  Perm J       Date:  2013

Review 3.  Minimal hepatic encephalopathy.

Authors:  Laura M Stinton; Saumya Jayakumar
Journal:  Can J Gastroenterol       Date:  2013-10       Impact factor: 3.522

Review 4.  Management of covert hepatic encephalopathy.

Authors:  Abhijeet Waghray; Nisheet Waghray; Kevin Mullen
Journal:  J Clin Exp Hepatol       Date:  2014-04-01

Review 5.  Management in acute liver failure.

Authors:  Subrat K Acharya
Journal:  J Clin Exp Hepatol       Date:  2014-12-03

6.  Current concepts in the pathophysiology and management of hepatic encephalopathy.

Authors:  R Todd Frederick
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-04

Review 7.  Effects of probiotics and commensals on intestinal epithelial physiology: implications for nutrient handling.

Authors:  Silvia C Resta
Journal:  J Physiol       Date:  2009-07-13       Impact factor: 5.182

Review 8.  Gut microbiota and liver diseases.

Authors:  Masami Minemura; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

Review 9.  Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota.

Authors:  Matteo Garcovich; Maria Assunta Zocco; Davide Roccarina; Francesca Romana Ponziani; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2012-12-14       Impact factor: 5.742

Review 10.  Disaccharides in the treatment of hepatic encephalopathy.

Authors:  Praveen Sharma; Barjesh Chander Sharma
Journal:  Metab Brain Dis       Date:  2013-03-02       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.